M. Lee et al. / European Journal of Medicinal Chemistry 46 (2011) 3099e3104
3103
determine its mechanism of action, cytotoxicity to other cancer cell
Appendix. Supplementary material
lines, and aqueous solubility.
Analog 1j was sent to the NCI (National Cancer Institute) for
further testing against a panel of 60 different human cancer cell
Supplementary data related to this article can be found online at
lines [18]. At a fixed concentration of 10 mM, compound 1j was
found to be cytotoxic and selective against certain human cancer
cell lines. It was most cytotoxic against SF-539 CNS cancer, MDA-
MB-435 melanoma, OVCAR-3 ovarian cancer, and HS-578T breast
cancer cells. The results are summarized in a figure given in the
supplementary materials section. In a separate study conducted in
our laboratory, the cytotoxicity of compound 1j against human
melanoma MDA-MB-435 was found using an SRB assay (48 h
References
[1] (a) G.R. Pettit, S.B. Singh, M.L. Niven, E. Hamel, J.M. Schmidt, Isolation, struc-
ture, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of
microtubule assembly, derived from Combretum caffrum, J. Nat. Prod. 50
(1987) 119e131;
(b) R.T. Dorr, K. Dvorakova, K. Snead, D.S. Alberts, S.E. Salmon, G.R. Pettit,
Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin
inhibitor, invest, New Drugs 14 (1996) 131e137.
exposure) to have an IC50 value of 0.90 mM [11], which is consistent
with NCI’s GI50 value for the same cells of 0.2 mM.
[2] C.M. Lin, S.B. Singh, P.S. Chu, R.O. Dempcy, J.M. Schmidt, G.R. Pettit, E. Hamel,
Interactions of tubulin with potent natural and synthetic analogs of the
antimitotic agent combretastatin: a structureeactivity study, Mol. Pharmacol.
34 (1988) 200e208.
[3] D.J. Chaplin, G.R. Pettit, S.A. Hill, Anti-vascular approaches to solid tumour
therapy: evaluation of combretastatin A4 phosphate, Anticancer Res. 19
(1999) 189e195.
[4] L. Vincent, P. Kermani, L.M. Young, J. Cheng, F. Zhang, K. Shido, G. Lam,
H. Bompais-Vincent, Z. Zhu, D.J. Hicklin, P. Bohlen, D.J. Chaplin, C. May, S. Rafii,
Combretastatin A-4 phosphate induces rapid regression of tumor neovessels
and growth through interference with vascular endothelial-cadherin
signaling, J. Clin. Invest. 115 (2005) 2992e3006.
[5] (a) G.R. Pettit, B.E. Toki, D.L. Herald, M.R. Boyd, E. Hamel, R.K. Pettit,
J.C. Chapuis, Antineoplastic agents. 410. Asymmetric hydroxylation of trans-
combretastatin A-41, J. Med. Chem. 42 (1999) 1459e1465;
(b) G.R. Pettit, M.R. Rhodes, D.L. Herald, D.J. Chaplin, M.R.L. Stratford, E. Hamel,
R.K. Pettit, J.C. Chapuis, D. Oliva, Antineoplastic agents 393. Synthesis of the trans-
isomer of combretastatin A-4 prodrug, Anticancer Drug Des. 13 (1998) 981e993.
[6] D.J. Chaplin, G.R. Pettit, C.S. Parkins, S.A. Hill, Antivascular approaches to solid
tumour therapy: evaluation of tubulin binding agents, Br. J. Cancer Suppl. 27
(1996) S86eS88.
2.4. Microtubule depolymerization
Further studies were conducted to determine the mechanism of
action for compound 1j and its methylpyrazoline derivatives. The
effect of compound 1j on interphase microtubules was examined
on A-10 aortic cells (See Fig. 3). The EC50 value, the concentration
that is required to cause 50% loss of cellular microtubules in
A-10 cells, was found to be 4.1
mM. The results were further
analyzed by calculating the ratio of EC50/IC50 (MDA-MB-435) for
analog 1j. Compounds that display a low ratio of EC50/IC50, such as
compound 4.5 for 1j, are expected to derive their cytotoxic activity
from causing microtubule depolymerization. For comparison, the
ratio of EC50/IC50 (MDA-MB-435) for CA-4 is 2.3 [11]. This suggests
that microtubule depolymerization is most likely the mechanism of
action for the methylpyrazoline analogs.
[7] (a) J.R. Wu-Wong, J.D. Alder, L. Alder, D.J. Burns, E.K.-H. Han, B. Credo, S.K. Tahir,
B.D. Dayton, P.J. Ewing, W.J. Chiou, Identification and characterization of A-
105972, an antineoplastic agent, Cancer Res. 61 (2001) 1486e1492;
(b) G.R. Pettit, S.B. Singh, E. Hamel, C.M. Lin, D.S. Alberts, D. Garcia-Kendall,
Isolation and structure of the Strong cell growth and tubulin inhibitor com-
bretastatin A-4, Experientia 45 (1989) 209e211;
2.5. Water solubility
(c) N.H. Nam, Combretastatin A-4 analogues as antimitotic antitumor agents,
Curr. Med. Chem. 10 (2003) 1697e1922;
(d) H.N. Pati, B.K. Mishra, B. Babu, S.G. Hiriyanna, Chemistry of combretastatin
and its analogs: an overview, Biomed 4 (2009) 1e22;
(e) A. Chaudhary, S.N. Pandeya, P. Kumar, P.P. Sharma, S. Gupta, N. Soni,
K.K. Verma, Combretastatin A-4 analogs as anticancer agents, Mini Rev. Med.
Chem. 7 (2007) 1186e1205;
(f) T. Brown, H. Holt Jr., M. Lee, Novel heterocyclic analogs of combretastatins,
Top. Heterocyl. Chem. 2 (2006) 1e52;
One important goal of this project was to design CA-4 analogs
that possess an increased solubility in biological media. Thus, the
lead compound 1j was subjected to a test in which the aqueous
solubility was measured. This assay utilized a modified version of
the Multi Screen Solubility Filter Plate protocol developed by Mil-
lipore [11]. The maximum aqueous solubility for the assay is
500
372
m
m
M, and the results showed that compound 1j had solubility of
M, which is slightly higher than that for CA-4, which was
(g) G.C. Tron, T. Pirali, G. Sorba, F. Pagliai, S. Busacca, A.A. Genazzani, Medicinal
chemistry of combretastatin A4: present and future directions, J. Med. Chem. 49
(2006) 3033e3044.
recorded as 350 mM [11].
[8] R. LeBlanc, J. Dickson, T. Brown, M. Stewart, H.N. Pati, D. VanDerveer,
H. Arman, J. Harris, W. Pennington, H. Holt Jr., M. Lee, Synthesis and cyto-
toxicity of Epoxide and pyrazole analogs of the combretastatins, Bioorg. Med.
Chem. 13 (2005) 6025e6034.
3. Conclusion
[9] M. Johnson, B. Younglove, L. Lee, R. LeBlanc, H. Holt Jr., H. Patrice, H. Mackay,
T. Brown, S.L. Mooberry, M. Lee, Design, synthesis, and biological testing of
pyrazoline derivatives of Combretastatin-A4, Bioorg. Med. Chem. Lett. 17
(2007) 5897e5901.
[10] J. Ruprich, A. Prout, J. Dickson, B. Younglove, L. Nolan, K. Baxi, R. LeBlanc,
L. Forrest, P. Hills, H. Holt Jr., H. Mackay, T. Brown, S.L. Mooberry, M. Lee,
Design, synthesis, and biological testing of cyclohexenone derivatives of the
combretastatins, Lett. Drug Des. Disc. 4 (2007) 144e148.
[11] L. Lee, M.R. Lyda, M. Lee, R. Davis, H. Mackay, S. Chavda, B. Babu, E.L. O’Brien,
A.L. Risinger, S.L. Mooberry, M. Lee, Design, synthesis, and biological evalua-
tions of 2,5-Diaryl-2,3-Dihydro-1,3,4-Oxadiazoline analogs of Combretastatin-
A4, J. Med. Chem. 53 (2010) 325e334.
[12] (a) F. Lara-Ochoa, G. Espinosa-Perez, A new synthesis of combretastatins A-
4 and AVE-8062A, Tetrahedron Lett. 48 (2007) 7007e7010;
In conclusion, methylpyrazoline compounds 1a-m are effec-
tive analogs of combretastatin A-4. Several derivatives are
cytotoxic against a wide variety of cancer cell lines grown in
culture. The mechanism of action of the most cytotoxic analog 1j
was found to be microtubule depolymerization, consistent with
the actions of CA-4. In addition, methylpyrazoline compounds
were found to have noteworthy advantages in comparison to CA-
4, which include increased water solubility and an easier
synthetic scheme.
(b) G.R. Pettit, M.R. Rhodes, D.L. Herald, E. Hamel, J.M. Schmidt, R.K. Pettit,
Antineoplastic agents. 445. Synthesis and evaluation of structural modifica-
tions of (Z)- and (E)-combretastatin A-41, J. Med. Chem. 48 (2005) 4087e4099.
[13] (a) N.H. Nam, Combretastatin A-4 analogues as antimitotic antitumor agents,
Curr. Med. Chem. 10 (2003) 1697e1722;
Acknowledgements
Support from Conjura Pharmaceuticals, LLC, (ML) and Hope
College-Arnold & Mabel Beckman Scholars Program (RS) is greatly
appreciated. Support by the President’s Council.
(b) H.N. Pati, B.K. Mishra, B. Babu, S.G. Hiriyanna, Chemistry of combretastatin
and its analogs: an overview, Biomed 4 (2009) 1e22;
(c) A. Chaudhary, S.N. Pandeya, P. Kumar, P.P. Sharma, S. Gupta, N. Soni,
K.K. Verma, Combretastatin A-4 analogs as anticancer agents, Mini-Reviews
Med. Chem. 7 (2007) 1186e1205;
(d) T. Brown, H. Holt Jr., M. Lee, Synthesis of biologically active heterocyclic stilbene
and chalcone analogs of combretastatin, Top. Heterocyl. Chem. 2 (2006) 1e52;
Research Excellence award (SLM) is gratefully acknowledged.
The X-ray diffractometer at Youngstown State University was fun-
ded by NSF Grant 0087210, Ohio Board of Regents Grant CAP-491,
and by Youngstown State University.